
C-Path Selects New Leaders of Data Science and Quantitative Medicine

TUCSON, Ariz., April 26, 2021 — [Critical Path Institute \(C-Path\)](#) has named Amanda J. Borens, M.S., as Executive Director of Data Science within C-Path’s Data Collaboration Center (DCC), and Jackson Burton, Ph.D., as Executive Director of C-Path’s Quantitative Medicine Program.



[Amanda Borens, MSc](#)

Executive Director of Data Science

Borens has been with C-Path for nearly five years and has more than 20 years of development, analytics and scientific experience in academia, clinical settings, health care informatics and biotech companies. She brings a wealth of practical experience and leadership to C-Path’s Data Collaboration Center.

“Time and again, Amanda has demonstrated her technical skills and experience in leading key C Path data collaboration projects to success,” said C-Path Chief Technology Officer and Data Collaboration Center Director Rick Liwski. “Every day, C Path relies on Amanda’s knowledge and experience to drive critical DCC programs and guide our data science strategy.”

Borens’ experience in the emerging field of data science led her to work in medical diagnostics, where she was part of a device development team that successfully achieved U.S. Food and Drug Administration clearance and CE Marking in Europe. Throughout her career, there has been a common thread of providing Big Data solutions to solve scientific problems and acting as the interface between life scientists and technology innovation.

As Executive Director of Data Science, Borens is responsible for leading the Data Science team, which aims to increase the FAIRness (findable, accessible, inoperable and reusable) of data by developing and integrating semantic standards, tools for consumption and sharing of data, performing data transformations that increase data accessibility, and by performing analyses that transform data into information — all core components of C-Path’s expertise. In addition to her management responsibilities, Borens also has the technical responsibility for the architecture and development of C-Path’s overall data and analytics platform strategy. The initial focus of her efforts has been on the Rare Disease Cure Accelerator–Data and Analytics

Platform (RDCA-DAP®) and the evolution of its data efforts moving forward.



Jackson Burton, PhD

Executive Director,
Quantitative Medicine Program

Burton obtained his doctoral degree in applied mathematics at the University of Arizona, where he focused on quantitative modeling of drug transport in solid tumors. Prior to joining C-Path, Burton worked in industry settings conducting modeling and statistical analyses for a variety of mission-driven quantitative solutions in oncology and business decision science. He has been with C-Path for four years.

As leader of C-Path's Quantitative Medicine Program, Burton oversees the organization's efforts in the development of innovative quantitative solutions to accelerate medical product development across therapeutic areas (including neurological disorders, diabetes, solid organ transplantation, rare/orphan diseases and pediatrics). Such solutions include clinical trial simulation tools, model-based biomarker tools, machine learning and AI for remote monitoring technologies, and evidence generation from real-world data. Additionally, he leads C-Path's postdoctoral fellowship program in model-informed drug development, where the next generation of cutting-edge scientists who will further transform medical product development paradigms are being trained.

"Jackson embodies the type of scientist needed to truly accelerate medical product development in the 21st century," said C-Path Chief Science Officer Klaus Romero, M.D., M.S., F.C.P. "With his expertise in integrating mathematics and medicine, and his ability to lead the team that transforms data into actionable solutions to accelerate and de-risk the R&D and regulatory process, the lives of countless patients will benefit from his leadership at C-Path."

For more information on C-Path's Data Collaboration Center, visit <https://c-path.org/programs/dcc>. For more information on C-Path's Quantitative Medicine Program, visit: <https://c-path.org/programs/quantmed>.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 55% funded by FDA/HHS, totaling \$14,575,306, and 45% funded by non-government source(s), totaling \$11,916,747. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government. For more information, please visit [FDA.gov](https://www.fda.gov).

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit www.c-path.org and c-path.eu.

Media Contact:

Kissy Black

C-Path

615.310.1894

kblack@c-path.org